Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.61 |
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.58 |
| ▸ | CNR1 | P21554 | 1/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | FABP7 | O15540 | 1/20 | 0.40 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.40 |
| ▸ | ELANE | P08246 | 4/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1072269 | 1.00 | TDP1 (0.61) | TDP1LMNAADRA2ACNR1ATM | |
| SCHEMBL523193 | 0.88 | TDP1 (0.76) | TDP1LMNAADRA2ACNR1ATM | |
| SCHEMBL3685832 | 0.88 | TDP1 (0.82) | TDP1LMNAADRA2ACNR1ATM | |
| SCHEMBL1073811 | 0.88 | TDP1 (0.82) | TDP1LMNAADRA2ACNR1ATM | |
| SCHEMBL1073814 | 0.88 | TDP1 (0.82) | TDP1LMNAADRA2ACNR1ATM | |
| SCHEMBL1070031 | 0.88 | TDP1 (0.48) | TDP1LMNAADRA2ACNR1ATM | |
| SCHEMBL1070035 | 0.88 | TDP1 (0.48) | TDP1LMNAADRA2ACNR1ATM | |
| SCHEMBL1074157 | 0.86 | TDP1 (0.63) | TDP1LMNAADRA2ACNR1ATM | |
| SCHEMBL1074161 | 0.86 | TDP1 (0.63) | TDP1LMNAADRA2ACNR1ATM | |
| SCHEMBL4433235 | 0.85 | TDP1 (0.76) | TDP1LMNAADRA2ACNR1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1797953-B1 | PROCESS FOR PRODUCING OXYGENIC COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2011-01-05 | — | — | EP | disclosed |
| US-7700799-B2 | Method for producing (2-formyl-1-alkenyl) cyclopropane compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-04-20 | — | — | US | disclosed |
| US-20090137839-A1 | METHOD FOR PRODUCING (2-FORMYL-1-ALKENYL) CYCLOPROPANE COMPOUND | SUMITOMO CHEMICAL COMPANY, LTD. (JP) | 2009-05-28 | — | — | US | disclosed |
| US-7498459-B2 | Method for producing (1-alkenyl)cyclopropane compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-03-03 | — | — | US | disclosed |
| US-20080064898-A1 | Method for Producing Oxygen-Containing Compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2008-03-13 | — | — | US | disclosed |
| US-7276622-B2 | Method for producing oxygen-containing compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-10-02 | — | — | US | disclosed |
| US-20070197818-A1 | Method for producing (1-alkenyl) cyclopropane compound | SUMITOMO CHEMICAL COMPANY, LIMITED | 2007-08-23 | — | — | US | disclosed |
| EP-1797953-A1 | PROCESS FOR PRODUCING OXYGENIC COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2007-06-20 | — | — | EP | disclosed |
| EP-1728781-A1 | PROCESS FOR PRODUCTION OF (1-ALKENYL)CYCLOPROPANES | Sumitomo Chemical Company, Limited (JP) | 2006-12-06 | — | — | EP | disclosed |
| US-20060173221-A1 | Method for producing oxygen-containing compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-08-03 | — | — | US | disclosed |
| EP-1609777-A1 | METHOD FOR PRODUCING OXYGEN-CONTAINING COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2005-12-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137839-A1 | METHOD FOR PRODUCING (2-FORMYL-1-ALKENYL) CYCLOPROPANE COMPOUND | ACSL3, ACSL1, ARL1 | TDP1 4458/4885LMNA 2696/4885ADRA2A 898/4885 |
| US-20080064898-A1 | Method for Producing Oxygen-Containing Compound | AOC2, AOX1, CAT | TDP1 4391/4885LMNA 3622/4885ADRA2A 3643/4885 |
| US-20060173221-A1 | Method for producing oxygen-containing compound | GPX4, DUOX2, SCO2 | TDP1 4530/4885LMNA 4036/4885ADRA2A 4831/4885 |
| US-20070197818-A1 | Method for producing (1-alkenyl) cyclopropane compound | ACSL3, ARL1, ACSL1 | TDP1 4490/4885LMNA 3763/4885ADRA2A 1424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.